Emerging therapies in head and neck cancers: EGFR inhibitors.
Held-Warmkessel
Jeanne
J
Fox Cancer Center, Philadelphia, PA, USA.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods / Q000451:nursing; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D024802:Nurse's Role; D009859:Oncology Nursing / Q000458:organization & administration*; D010347:Patient Care Planning / Q000458:organization & administration; D010353:Patient Education as Topic; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors